New topics in bradykinin research

Marcus Maurer(Charité - Universitätsmedizin Berlin), Michael Bäder(Max Delbrück Center), Murat Baş(TUM Klinikum), Fleur Bossi(University of Trieste), Marco Cicardi(University of Milan), Massimo Cugno(University of Milan), Peter Howarth(University of Southampton), Allen P. Kaplan(Medical University of South Carolina), Georg Kojda(Düsseldorf University Hospital), F Leeb-Lundberg(Lund University), Jan Lötvall(University of Gothenburg), Markus Magerl(Charité - Universitätsmedizin Berlin)
Allergy
August 22, 2011
Cited by 174Open Access
Full Text

Abstract

To cite this article : Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M, Howarth P, Kaplan A, Kojda G, Leeb‐Lundberg F, Lötvall J, Magerl M. New topics in bradykinin research. Allergy 2011; 66 : 1397–1406. Abstract Bradykinin has been implicated to contribute to allergic inflammation and the pathogenesis of allergic conditions. It binds to endothelial B 1 and B 2 receptors and exerts potent pharmacological and physiological effects, notably, decreased blood pressure, increased vascular permeability and the promotion of classical symptoms of inflammation such as vasodilation, hyperthermia, oedema and pain. Towards potential clinical benefit, bradykinin has also been shown to exert potent antithrombogenic, antiproliferative and antifibrogenic effects. The development of pharmacologically active substances, such as bradykinin receptor blockers, opens up new therapeutic options that require further research into bradykinin. This review presents current understanding surrounding the role of bradykinin in nonallergic angioedema and other conditions seen by allergists and emergency physicians, and its potential role as a therapeutic target.


Related Papers

No related papers found

Powered by citation graph analysis